Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Non Operating Income: 2022-2025

Historic Other Non Operating Income for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$28,471.

  • InMed Pharmaceuticals' Other Non Operating Income fell 395.15% to -$56,994 in Q3 2025 from the same period last year, while for Sep 2025 it was -$104,775, marking a year-over-year decrease of 1892.25%. This contributed to the annual value of -$28,471 for FY2025, which is 54.02% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other Non Operating Income stood at -$28,471 for FY2025, which was up 54.02% from -$61,921 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Other Non Operating Income high stood at -$28,471 for FY2025, and its period low was -$117,551 during FY2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Other Non Operating Income value was -$48,175 (recorded in 2023), while the average stood at -$46,189.
  • In the last 5 years, InMed Pharmaceuticals' Other Non Operating Income surged by 59.02% in 2023 and then fell by 28.53% in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' Other Non Operating Income (Yearly) stood at -$117,551 in 2022, then spiked by 59.02% to -$48,175 in 2023, then fell by 28.53% to -$61,921 in 2024, then surged by 54.02% to -$28,471 in 2025.